24th week of 2020 patent applcation highlights part 28 |
Patent application number | Title | Published |
20200181164 | Thienopyranones and Furanopyranones as Checkpoint Inhibitors and Modulators of Anti-Tumor Immunity - The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral, bacterial or fungal infection, atherosclerosis, Type 1 or 2 diabetes, obesity, inflammatory disease, and/or SYK-associated disorder including by modulating biological processes through the inhibition of SYK alone, or in combination with inhibition of one or more of PI3 kinase including PI3K-gamma isoform, BET bromodomain proteins, CDK 4/6, and checkpoint proteins, comprising the administration of a compound(s) of Formula I-V (or pharmaceutically acceptable salts thereof) as defined herein. | 2020-06-11 |
20200181165 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME - Provided is a compound of Chemical Formula 1: | 2020-06-11 |
20200181166 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 - Disclosed herein are pyrido[3′,2′:4,5]thieno[2,3-d]pyridazin-8-amine and thieno[2,3-c:4,5-d′]dipyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M | 2020-06-11 |
20200181167 | METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS - The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl and alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propylheptyllmorpholino)ethan-1-ol with the INN name delmopinol. The invention also relates to 1-chloro-4-propylhept-3-ene, 1-iodo-4-propylhept-3-ene, 8a-(4-5 propylheptyl)hexahydrooxazolo[2,3-c] [1,4]oxazine, 8a-(4-propylhept-3-en-1-yl)hexahydrooxazo-lo[2,3-c][1,4]oxazine and 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol which are intermediates in the delmopinol process. | 2020-06-11 |
20200181168 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 - The present invention relates to compounds of formula I: | 2020-06-11 |
20200181169 | NOVEL POLYMORPHS OF DOLUTEGRAVIR AND SALTS THEREOF - The present invention relates to novel crystalline forms of dolutegravir, process for its preparation and pharmaceutical composition comprising them. | 2020-06-11 |
20200181170 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. | 2020-06-11 |
20200181171 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS - The invention relates to thiazolopyridine derivatives of the general formula I, | 2020-06-11 |
20200181172 | HETEROCYCLE DERIVATIVES AS PESTICIDES - The present invention relates to novel fused bicyclic heterocycle derivatives of formula (I) | 2020-06-11 |
20200181173 | METHOD FOR PREPARING PHENYLBORONIC ACID NEOPENTYL GLYCOL ESTER - The present invention discloses a method for preparing a phenylboronic acid neopentyl glycol ester. A mixed nickel(II) complex with a formula of Ni[P(OR | 2020-06-11 |
20200181174 | BORON-CONTAINING COMPOUNDS - Described herein are boron-containing compounds, compositions, and methods for their preparation. | 2020-06-11 |
20200181175 | BORONIC DERIVATIVES OF HYDROXAMATES AS ANTICANCER AGENTS - The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamates as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy. | 2020-06-11 |
20200181176 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2020-06-11 |
20200181177 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs). | 2020-06-11 |
20200181178 | PREPARATION OF TRIIODOSILANES - Provided is a process for preparing certain silane precursor compounds, e.g., triiodosilane from trichlorosilane utilizing lithium iodide in powder form and catalyzed by tertiary amines. The process provides triiodosilane in high yields and high purity. Triiodosilane is a precursor compound useful in the atomic layer deposition of silicon onto various microelectronic device structures. | 2020-06-11 |
20200181179 | METHODS FOR THE PURIFICATION OF L-GLUFOSINATE - Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate. In some embodiments, a portion of the glutamate in the starting composition may be separated from the L-glufosinate using a crystallization step. Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are also described. | 2020-06-11 |
20200181180 | METHOD FOR PREPARING SENSITIZING MATERIAL AND ORGANIC LIGHT EMITTING DIODE - A method for preparing a sensitizing material and an organic light emitting diode are provided, the method including: adding C | 2020-06-11 |
20200181181 | METHOD FOR PRODUCING CYCLOMETALATED IRIDIUM COMPLEX - The present invention provides a method for producing a cyclometalated iridium complex, the method including producing a cyclometalated iridium complex by reacting a cyclometalated iridium complex raw material including an organoiridium compound with an aromatic heterocyclic bidentate ligand capable of forming an iridium-carbon bond and an iridium-nitrogen bond, and using as the raw material an organoiridium compound including a substructure represented by the following General Formula (1). The present invention is capable of producing a cyclometalated iridium complex with a high yield without by-production of a halogen-crosslinked iridium dimer. | 2020-06-11 |
20200181182 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A neutral Ir compound having a first ligand L | 2020-06-11 |
20200181183 | PROCESS FOR PREPARING PLATINUM ORGANOSILOXANE COMPLEXES - A platinum organosiloxane complex is prepared by a process including 1) combining A) a platinous halide and B) a ketone, and thereafter 2) adding C) a polyorganosiloxane having, per molecule, 2 to 4 silicon bonded terminally unsaturated hydrocarbon groups having from 2 to 6 carbon. The platinum organosiloxane complex prepared by the process is useful as a hydrosilylation catalyst. | 2020-06-11 |
20200181184 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND - An organometallic compound represented by Formula 1: | 2020-06-11 |
20200181185 | PAYLOAD AND LINKER DESIGNS FOR PLATINUM-ACRIDINE ANTICANCER AGENTS AND METHODS THEREOF - The present invention relates to payloads containing functionalized platinum-(benz)acridine hybrid agents as cytotoxic warheads and a method of synthesizing the payloads. The payload can be regioselectively conjugated to a biologically active moiety in order to facilitate the delivery and/or enhance the activity of the platinum compound. | 2020-06-11 |
20200181186 | SYNTHESIS OF PHOSPHATE DERIVATIVES - The present invention generally relates to a process for the preparation of certain anticancer compounds as specific phosphate diastereoisomers. | 2020-06-11 |
20200181187 | PROCESS FOR THE PREPARATION OF (S,S)-SECOISOLARICIRESINOL DIGLUCOSIDE AND (R,R)-SECOISOLARICIRESINOL DIGLUCOSIDE - Provided is a synthesis process for (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside. | 2020-06-11 |
20200181188 | CRYSTALLINE FORMS OF NICOTINOYL RIBOSIDES AND DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF - The present disclosure provides crystalline Form II of nicotinic acid riboside, crystalline Form II of nicotinic acid riboside triacetate, and methods of preparation thereof. | 2020-06-11 |
20200181189 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS - Disclosed are chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours in | 2020-06-11 |
20200181190 | SYNTHESIS OF 3'-DEOXYADENOSINE-5'-O-[PHENYL(BENZYLOXY-L-ALANINYL)]PHOSPHATE (NUC-7738) - The present invention generally relates to a novel process for the preparation of 3′-deoxyadenosine derivatives, and particularly NUC-7738 (3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate) an anticancer ProTide of deoxyadenosine. | 2020-06-11 |
20200181191 | POTENT SOFT ANTI-INFLAMMATORY CORTICOSTEROID COMPOUNDS AND USES THEREOF - Potent soft corticosteroid pharmaceutical compositions comprising them and method for use as anti-inflammatory agents. Also, a method for softening fluticasone propionate and similar corticosteroids to arrive at potent but safer alternatives. The compound 5-fluoromethyl 17α-dichloroacetoxy-6α,9α-difluoro-11β-hydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, which is equally potent to but safer than fluticasone, is among those provided. Another compound of particular interest is 2-hydroxyethyl 17α-dichloroacetoxy-6α,9α-difluoro-11β-hydroxy-16β-methyl-3-oxoandrosta-1,4-diene-17β-carboxylate. | 2020-06-11 |
20200181192 | DISULFIDE BIOCONJUGATION - Compounds and methods are provided for one-step functionalization of disulfide bonds in proteins. | 2020-06-11 |
20200181193 | IMPROVED METHODS OF ANTIBODY PRODUCTION THAT MINIMIZE DISULFIDE BOND REDUCTION - The present disclosure discloses methods for purifying antibodies providing an air overlay or headspace to single-use storage bags containing the antibody during purification. In specific embodiments, the application relates to purification of antibodies to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), such as antibody 22G2, which decrease unwanted disulfide bond reduction. The application further provides depth filtration at lower throughput and/or flux, which also minimizes unwanted disulfide bond reduction. | 2020-06-11 |
20200181194 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES - Compounds of Formula (I)a or (I)b: | 2020-06-11 |
20200181195 | MUC1-DERIVED PEPTIDE, AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CANCER, IMMUNITY-INDUCING AGENT AND METHOD FOR MANUFACTURING ANTIGEN PRESENTING CELL USING SAME - The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues. | 2020-06-11 |
20200181196 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE - The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc. | 2020-06-11 |
20200181197 | THERAPEUTIC PEPTIDES - Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism. | 2020-06-11 |
20200181198 | Peptides for Binding Epidermal Growth Factor - A polypeptide having a sequence at least 70% identical to SEQ ID NO: 1 (YVSPGMKNVNWWSHWWHATD) is provided. The polypeptide includes no more than 100 total amino acid residues. | 2020-06-11 |
20200181199 | Compstatin Analogs With Increased Solubility And Improved Pharmacokinetic Properties - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus and/or C-terminus contains an added component that improves (1) the peptide's solubility at physiological pH; (2) the peptide's plasma half-life; (3) the peptide's intraocular retention; and/or (4) the peptide's binding affinity to C3 or its fragments as compared to an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed. | 2020-06-11 |
20200181200 | NOVEL METHOD FOR SYNTHESIZING AMANITINS - The invention relates to novel methods for synthesizing amanitin derivatives having a hydroxy group attached to the central tryptophan moiety. The invention furthermore relates to novel amanitin derivatives having a hydroxy group attached to position 4′, 5′ or 7′ of the central tryptophan moiety, novel conjugates of such amanitin derivatives, and pharmaceutical compositions comprising such conjugates. | 2020-06-11 |
20200181201 | TARGETING ALPHA2DELTA-1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS - The present disclosure provides α2δ-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an α2δ-1 C-terminal domain peptide which blocks binding of α2δ-1 to the glutamate receptors NMDAR and AMPAR. | 2020-06-11 |
20200181202 | POLYPEPTIDE-BASED SHUTTLE AGENTS FOR IMPROVING THE TRANSDUCTION EFFICIENCY OF POLYPEPTIDE CARGOS TO THE CYTOSOL OF TARGET EUKARYOTIC CELLS, USES THEREOF, METHODS AND KITS RELATING TO SAME - The present description relates to synthetic peptides useful for increasing the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells. More specifically, the present description relates to synthetic peptides and polypeptide-based shuttle agents comprising an endosome leakage domain (ELD) operably linked to a cell penetrating domain (CPD), or an ELD operably linked to a histidine-rich domain and a CPD. Compositions, kits, methods and uses relating to same are also described. | 2020-06-11 |
20200181203 | COVALENTLY FUSED VIRAL COAT PROTEINS FOR THE DISPLAY OF TARGET MOLECULES - A fusion protein comprising a first recombinant viral coat protein, a second recombinant viral coat protein and a first linkage peptide is provided. The first recombinant viral coat protein is linked to N-terminus of the first linkage peptide. The second recombinant viral coat protein is linked to C-terminus of the first linkage peptide. The first and second recombinant viral coat proteins are derived from the coat protein (CP) of alfalfa mosaic virus (AIMV). The fusion protein may form a virus like particle (VLP). Where the fusion protein further comprises a target protein, the target protein may be displayed on the surface of the VLP. Also provided are methods for producing the fusion protein and the VLP as well as the uses of the fusion protein and/or the VLP. | 2020-06-11 |
20200181204 | NON-IMMUNOGENIC PROTEIN NANOPARTICLES WITH CANCER TARGETING ACTIVITY USING ABMUMIN-BINDING PEPTIDE - The present invention relates to recombinant self-assembling protein nanoparticles presenting an albumin-binding peptide at the surface. For the recombinant self-assembling protein nanoparticles according to the present invention, an albumin-binding peptide can reduce the immunogenicity of the recombinant self-assembling protein nanoparticles because the albumin-binding peptide is presented at the surface, and thus binds to an albumin protein present in vivo, and the albumin-binding peptide can also provide the cancer delivery function of the recombinant self-assembling protein nanoparticles because the albumin-binding peptide binds to albumin around cancer. Simultaneously, the binding of the albumin-binding peptide to albumin can significantly increase the in vivo residence time of the recombinant self-assembling protein nanoparticles, thus increasing the potential for use in various medical applications. | 2020-06-11 |
20200181205 | ENGINEERING OF MONOMERIC, RED-SHIFTED, AND BRIGHTER VARIANTS OF iRFP USING STRUCTURE-GUIDED MULTI-SITE MUTAGENESIS - The invention in at least one embodiment includes a method to convert a fluorescent protein into a modified fluorescent protein in a monomeric state where a dimerization interface is identified in a template protein in a homodimer state. One or more targeted mutation(s) are introduced at the dimerization interface to disrupt dimerization and favor the monomeric state. In another embodiment of the invention, one or more chromophore binding domains are identified in a template protein. One or more targeted mutations are introduced in the chromophore binding domain(s) to change the configuration of a biliverdin chromophore in the template protein from a 15Z anti configuration to a 15E anti configuration. | 2020-06-11 |
20200181206 | PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS - The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis. | 2020-06-11 |
20200181207 | ANALYTICAL AND THERAPEUTIC METHODS AND COMPOSITIONS, AND USES THEREOF - The invention generally relates to compositions and methods for treating, detecting and assisting in the diagnosis of | 2020-06-11 |
20200181208 | ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY - The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer. | 2020-06-11 |
20200181209 | Tuberculosis Compositions And Methods Of Treating Or Preventing Tuberculosis - The present disclosure provides fusion proteins comprising | 2020-06-11 |
20200181210 | MODIFIED CYCLIC PEPTIDES AND THERAPEUTIC USE THEREOF - The present invention relates to cyclic peptide structures possessing the ability to incorporate and deliver peptides of sizable length (e.g., peptides of twenty amino acid residues or more in length), while retaining properties of cyclic peptides and/or cyclotides, including, e.g., protease resistance, heat resistance, resistance to low pH, etc. Methods for preparing cyclic peptide compositions, assessing the extent of cyclization within a peptide population, as well as methods for using cyclic peptide compositions are also provided. | 2020-06-11 |
20200181211 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY - The present invention is directed to a composition comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic agent, a nucleic acid encoding a fusion polypeptide comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic polypeptide agent as well as a corresponding recombinant vector and host cell comprising such a nucleic acid and preferably expressing said fusion polypeptide. The invention also relates to a kit of parts comprising at least one fibronectin binding polypeptide (FnBP), at least one diagnostic or therapeutic agent, and optionally one or more chemical agents for linking the fibronectin binding polypeptide (FnBP) to the diagnostic or therapeutic agent. In addition, the present invention intends said composition, nucleic acid, vector, host cell and kit for use in the therapeutic or prophylactic treatment of a disease, preferably a disease associated with abnormal fibronectin accumulation such as cancer, fibrosis or immune diseases. | 2020-06-11 |
20200181212 | ARTIFICIALLY ACTIVATED PEPTIDES - Described are the artificially induced conversion of certain toxic peptides to create both different forms of those peptides and new and useful derivatives of the original peptides that are both useful by themselves and useful as new compounds and new stable intermediates that may be used to make other important compounds. | 2020-06-11 |
20200181213 | Silk Nanofibrils and Uses Thereof - The present invention, in some aspects, provides compositions including a solution comprising a plurality of exfoliated silk microfibrils and/or exfoliated silk nanofibrils, wherein the micro- or nano-fibrils are characterized as having a substantially nematic structure, as well as methods for making and using the same. | 2020-06-11 |
20200181214 | FUSION PROTEINS FOR INHIBITING ANGIOGENESIS - The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same. | 2020-06-11 |
20200181215 | BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USE - The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use. | 2020-06-11 |
20200181216 | HSA-GDF-15 FUSION POLYPEPTIDE AND USE THEREOF - The disclosure relates to fusion polypeptides comprising serum albumin or a functional variant thereof and GDF15 protein or a functional variant thereof, and to pharmaceutical compositions that contain the fusion polypeptides, nucleic acids that encode the fusion polypeptides, methods of making the polypeptides and use of the polypeptides to decreasing appetite, decreasing body weight and treating metabolic diseases. | 2020-06-11 |
20200181217 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2020-06-11 |
20200181218 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2020-06-11 |
20200181219 | NSP-INTERLEUKIN-10 PROTEINS AND USES THEREOF - Disclosed herein are Nsp-IL10 polypeptides comprising an Nsp polypeptide and an IL10 polypeptide. In some embodiments, Nsp-IL10 polypeptide is capable of activating an NGF signaling pathway, an IL10 signaling pathway, or both. Also disclosed are methods for treating a disease comprising administering an Nsp-IL10 polypeptide. The methods include treating diseases associated with joint inflammation, such as osteoarthritis. | 2020-06-11 |
20200181220 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES - Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates). | 2020-06-11 |
20200181221 | PHOSPHATIDYLSERINE TARGETING FUSION MOLECULES AND METHODS FOR THEIR USE - Fusion molecules of a cytokine or portion thereof and a polypeptide which targets the fusion protein to phosphatidylserine, pharmaceutical compositions thereof, and methods for their use in targeting a cytokine or portion thereof to a pathological site and treating a disease or condition responsive to cytokine treatment are provided. | 2020-06-11 |
20200181222 | INSULIN DEGLUDEC FOR IMPROVEMENT OF GLYCAEMIC CONTROL AND REDUCTION OF ACUTE AND LONG-TERM DIABETES COMPLICATIONS - The present invention relates to insulin degludec for use in medicine. | 2020-06-11 |
20200181223 | INSULIN CONJUGATES - The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin. | 2020-06-11 |
20200181224 | NOVEL RECOMBINANT KLOTHO PROTEINS AND COMPOSITIONS AND METHODS INVOLVING SAME - Recombinant Klotho proteins, nucleic acids encoding the same, cell lines and cultures expressing the same, and method of manufacturing and administering the same are disclosed. Proteins have at least 80% amino acid sequence identity to a portion of human alpha Klotho and preferably a solubility or half-life-extending feature such as glycosylation and/or fusion protein tag. Treatment protocols include determining Klotho levels in a subject, calculating a dosage of the protein sufficient to raise the Klotho level in the subject to a predetermined level, administering the dosage to the subject, determining a rate of protein decline in the subject following administration of the protein, calculating a time and/or amount of a subsequent dosage of the protein, and/or administering the subsequent dosage to the subject. Proteins and related treatments for addressing aging-associated and other conditions are disclosed. | 2020-06-11 |
20200181225 | ENGINEERED T-CELL MODULATING MOLECULES AND METHODS OF USING SAME - Provided herein are engineered nucleic acids, engineered mRNAs, engineered polypeptides, and engineered pentamerized polypeptides, human and murine, each of which include sequences of VISTA, ICOS-L, PD-L1 or B7-H4 extracellular domains GO operably linked to the pentamerization domain of COMP. A soluble form of the pentamerized polypeptides has T-cell inhibitory activity, in the case of VISTA, PD-L1 or B7H4, or T-cell stimulatory activity, in the case of ICOS-L. Methods of using same for treatment of a subject in need of T-cell modulating activity are provided. | 2020-06-11 |
20200181226 | ANTIBODY-COUPLED T CELL RECEPTOR CONSTRUCTS AND THERAPEUTIC USES THEREOF - Disclosed herein are antibody-coupled T cell receptor (ACTR) polypeptides comprising: a CD16A extracellular domain, a transmembrane domain, one or more co-stimulatory signaling domains, at least one of which is a CD28 co-stimulatory signaling domain, and a CD3z cytoplasmic signaling domain. Also disclosed herein are genetically engineered immune cells, expressing: a first polypeptide which is an antibody-coupled T cell receptor (ACTR); and a second polypeptide that elicits a co-stimulatory signal as well as methods of enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a therapeutic antibody and an effective amount of immune cells (e.g., T lymphocytes and/or NK cells) expressing an antibody-coupled T-cell receptor (ACTR) polypeptide. | 2020-06-11 |
20200181227 | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 - Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme). | 2020-06-11 |
20200181228 | UNIVERSAL CHIMERIC ANTIGEN EXPRESSING IMMUNE CELLS FOR TARGETING OF DIVERSE MULTIPLE ANTIGENS AND METHOD OF MANUFACTURING THE SAME AND USE OF THE SAME FOR TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS - The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer. | 2020-06-11 |
20200181229 | HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF - The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V | 2020-06-11 |
20200181230 | HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF - The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V | 2020-06-11 |
20200181231 | sPD-1 VARIANT - FC FUSION PROTEINS - The invention is directed to novel sPD-1 variant—Fc fusion proteins. | 2020-06-11 |
20200181232 | CELL - The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22. | 2020-06-11 |
20200181233 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-06-11 |
20200181234 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF - Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease. | 2020-06-11 |
20200181235 | METHODS OF USE OF SOLUBLE CD24 FOR NEUROPROTECTION AND REMYELINATION - The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders | 2020-06-11 |
20200181236 | BISPECIFIC FUSION PROTEIN FOR IL-17 AND TNF-alpha - The present invention belongs to the technical field of biology, and particularly relates to a bispecific fusion protein for IL-17 and TNF-α, and a preparation method and use thereof. The bispecific fusion protein for IL-17 and TNF-α of the present invention is a dimer, each includes three structural function areas, and the three structural function areas are a TNF-α receptor fragment, an Fcγ fragment and an IL-17 receptor fragment. The bispecific fusion protein provided by the present invention includes the IL-17 receptor fragment and the TNF-α receptor fragment, can effectively bind to IL-17 and/or TNF-α, respectively and has high bioactivity, specificity and stability. | 2020-06-11 |
20200181237 | MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME - The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus). | 2020-06-11 |
20200181238 | TRANSDUCED T CELLS EXPRESSING HUMAN SSTR2 AND APPLICATION THEREOF - The present invention is directed to transduced T cells expressing at least 100,000 molecules of human somatostatin receptor 2 (SSTR2), which improves PET/CT imaging sensitivity. The present invention is also directed to transduced T cells expressing SSTR2 and chimeric antigen receptor (CAR). In one embodiment, the CAR is specific to human ICAM-1 and the CAR comprises a binding domain that is scFv of anti-human ICAM-1, or an I domain of the αL subunit of human lymphocyte function-associated antigen-1. In another embodiment, the CAR is specific to human CD19, and the CAR comprises a binding domain that is scFv of anti-human CD19. The present invention is further directed to using the above transduced T cells for monitoring T cell distribution in a patient by PET/CT imaging and/or treating cancer. | 2020-06-11 |
20200181239 | SCAFFOLD PROTEINS - The invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to 19, 21 to 25, 27 to 28, 35 to 37, 39, 41, 43 to 44, 46 to 47, 49 to 50, 52 to 53, 55 to 58, 63 to 64, 66, 68 to 82, 84 to 85, and 87 to 98 of SEQ ID NO: 1; characterised in that said polypeptide comprises one or more mutations relative to SEQ ID NO: 1 selected from the group consisting of: T51L, T51V, M65V, N32G, A59I, L38A, V20I, A40I, L38V, A12I, A12V, I16L, V20L, Q26E, E29M, T31K, N32D, N32H, T34V, T34R, T34D, T34P, A40V, Q42D, T45I, T45V, V48E, V48G, V48A, T51F, T51A, A59L, L67I, (V20I, L38A), (V20L, L38A), (V20I, L38V), (V20L, L38V), (E29K, K30E, E33K), (Y54D, T83D, Q86E), (A59L, G60N, D61G, N62K), (A59V, D61N, N62K), (G60N, D61G, N62K), (G60N, ΔD61, N62G), ΔD61, (A59L, G60N, ΔD61, N62G), (A59V, G60N, D61G, N62K), (A59I, G60N, D61G, N62K), (A59I, G60N, ΔD61, N62G), (A59V, G60N, ΔD61, N62G), (A59V, ΔD61), (G60P, ΔD61, N62P), (G60P, D61P, N62K), (G60P, ΔD61, N62G), (G60P, D61G, N62K), (D61N, N62K) and (T83D, Q86E). The invention also relates to various methods and nucleic acids. | 2020-06-11 |
20200181240 | COMPOSITIONS COMPRISING RESURFACED CELL-PENETRATING NANOBODIES AND METHODS OF USE THEREOF - The disclosure encompasses resurfaced cell-penetrating nanobodies and their methods of use. The resurfacing of nanobodies with positively-charged amino acids facilitates their penetration into a cell and allows targeting of a specific intracellular protein. | 2020-06-11 |
20200181241 | ULTRALONG COMPLEMENTARITY DETERMINING REGIONS AND USES THEREOF - Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject. | 2020-06-11 |
20200181242 | Compositions and Methods for Identifying and Sorting Antigen-Specific B Cells - The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. Specifically, the disclosure provides a construct useful in expressing biotinylated antigen monomers, said construct comprising a viral protein of an ectodomain of Hepatitis C Virus (HCV) envelope glycoprotein E2 or Human Immunodeficiency Virus (HIV) gp140. Further disclosed are methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto. | 2020-06-11 |
20200181243 | FORMULATIONS OF ANTIBODY MOLECULES TO INFLUENZA VIRUS - This disclosure relates to formulations of peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use. | 2020-06-11 |
20200181244 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE - Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD. | 2020-06-11 |
20200181245 | COMPOSITIONS TARGETING 3-REPEAT TAU FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, provided are compositions such as antibodies, e.g., single chain antibodies, that target 3-repeat (3R) Tau for the treatment of neurodegenerative disorders and taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation, and methods for making and using them. In alternative embodiments, provided are brain-penetrating antibodies that specifically recognize 3R Tau, and methods of using them to treat, ameliorate, prevent or decrease the symptoms of neurodegenerative disorders including taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation. Provided are methods for diagnosing a neurodegenerative disorder or a taupathy or any disorder or condition associated with a 3R Tau accumulation, and optionally the taupathy is Alzheimer's Disease, Pick's Disease or Fronto-temporal lobar degeneration. | 2020-06-11 |
20200181246 | CHIMERIC ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES - A chimeric mouse-human antibody for treatment of amyloid deposition diseases, pharmaceutical compositions comprising the antibody, methods and materials for producing the antibody, and methods for treating an amyloid deposition disease using the antibody and the pharmaceutical composition. | 2020-06-11 |
20200181247 | Antibodies to Amyloid Beta - The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies. Also provided are chimeric or humanized antibodies, including antibodies having CDRs in Table 2 and/or having a sequence as set forth in Table 4B or a sequence with at least 50% sequence identity thereto optionally wherein the CDR amino acid sequences are as set for forth in SEQ ID Nos: 74-79. Also provided are methods and uses thereof as well as kits comprising said antibodies. | 2020-06-11 |
20200181248 | ANTIBODY AGAINST SECRETED N-TERMINAL PEPTIDE OF GPC3 PRESENT IN BLOOD OR C-TERMINAL PEPTIDE OF GPC3 - Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells. | 2020-06-11 |
20200181249 | FUSION PROTEIN CONSTRUCTS FOR COMPLEMENT ASSOCIATED DISEASE - Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions. | 2020-06-11 |
20200181250 | ANTI-TRANSTHYRETIN HUMAN ANTIBODY - A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body. | 2020-06-11 |
20200181251 | LRRC33 INHIBITORS AND USE THEREOF - Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells. | 2020-06-11 |
20200181252 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 2020-06-11 |
20200181253 | TREATMENT FOR ADVERSE IMMUNE REACTION TO METAL IMPLANT DEBRIS - Described herein is a method for treating or prophylaxis of adverse immune reaction to metal debris, metal induced delayed type hypersensitivity (DTH), or inflammatory osteolysis by attenuating the inflammatory response. In one aspect, the method involves inhibiting the nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome/caspase-1 pathway or neutralizing or blocking the activity of interleukin 17 (IL-17), IL-17 receptor (IL-17R), IL-1R, IL-1(3, IL-18, IL-21, IL-23 with anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, anti-IL-1, anti-IL-1β, anti-IL-18, anti-IL-21, anti-IL-23, anti-IL-1R, soluble IL-17 receptors, soluble IL-1 receptors, soluble IL-18 receptors, soluble IL-21 receptors, IL-17 receptor inhibitors, IL-1 receptor inhibitors, IL-18 receptor inhibitors, IL-21 receptor inhibitors, IL-23 receptor inhibitors, blocking agents, inflammasome inhibitors, or combinations thereof. | 2020-06-11 |
20200181254 | VACCINE COMPOSITION COMPRISING A MUTANT OF HUMAN INTERLEUKIN-15 - Vaccine composition containing a mutant of the human Interleukin-15 (IL-15). The use of said mutant polypeptide of human IL-15 to manufacture a medicament for the active immunotherapy of diseases associated with IL-15 overexpression, including some autoimmune diseases and hematological malignancies. Administration to an individual that needs it of a therapeutically effective amount of the vaccine, that comprises the mutant polypeptide of the human IL-15 of the invention, constitutes a method for the therapy of IL-15 over-expressing related diseases. | 2020-06-11 |
20200181255 | Human IL-23 Antigen Binding Proteins - Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided. | 2020-06-11 |
20200181256 | ANTI SEZ6 ANTIBODIES AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 2020-06-11 |
20200181257 | MODIFIED Fc REGION OF ANTIBODY - Polypeptides with improved stability as compared to that of a parent polypeptide were successfully obtained by modifying at least one amino acid in a loop region of the antibody Fc region. Furthermore, by combining multiple amino acid modifications in the loop region, polypeptides with maintained or enhanced FcγR-binding activity as well as improved thermal stability, polypeptides with decreased FcγR-binding activity as well as improved thermal stability, and polypeptides with not only improved thermal stability and adjusted FcγR-binding activity but also decreased aggregate content, as compared to those of a parent polypeptide, were successfully obtained. | 2020-06-11 |
20200181258 | MODIFIED ANTIBODY CONSTANT REGION - The present invention relates to a canine IgG Fc domain, the amino acid sequence of which comprising at least one mutation selected among:—the substitution of amino acid 15.1 of CH2 domain according to the IMGT numbering system for C-domain with tyrosine;—the substitution of amino acid 16 of CH2 domain according to the IMGT numbering system for C-domain with threonine; and—the substitution of amino acid 18 of CH2 domain according to the IMGT numbering system for C-domain with glutamic acid. The present invention also relates to an Fc-fusion protein, comprising the canine IgG Fc domain, that is genetically linked to a peptide or a protein or an engineered ligand-binding proteins or a VHH domain, and to an antibody comprising the canine IgG Fc domain. | 2020-06-11 |
20200181259 | ANTI-CD47 ANTIBODIES AND USES THEREOF - The present invention is directed to a novel antibody against CD47 and the antibody fragments thereof and a composition comprising the antibody or antibody fragments thereof. The present invention relates further to a nucleic acid encoding the antibodies or antibody fragments thereof and host cells comprise the same, as well as the relevant use of the same. In addition, the present invention is also directed to the use of these antibodies and antibody fragments in the therapy and diagnosis. | 2020-06-11 |
20200181260 | BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY - Disclosed are compositions and methods for gene transfer in immune effector cells, e.g. to create chimeric antigen receptors (CARs). In particular, polypeptides are disclosed that comprising an antigen-binding region and a heparin binding domain, wherein the antigen-binding region is capable of specifically binding to an immune cell antigen located on an immune effector cell, and wherein the heparin binding domain is capable of binding a viral vector. | 2020-06-11 |
20200181261 | ANTI-CEACAM6 ANTIBODIES AND USES THEREOF - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and | 2020-06-11 |
20200181262 | HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES - Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders. | 2020-06-11 |
20200181263 | HETERO-DIMERIC MULTI-SPECIFIC ANTIBODY FORMAT TARGETING AT LEAST CD3 AND HSA - This invention relates to novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned tandem on two separate protein chains, respectively. | 2020-06-11 |